US equities |
MU $1,088.00 ▲+0.00% NVDA $237.47 ▲+0.00% SNDK $1,692.42 ▲+0.00% INTC $113.12 ▲+0.00% AMD $645.86 ▲+0.00% SPCX $167.60 ▲+0.00% PLTR $194.12 ▲+0.00% SKHY $178.25 ▲+0.00%
FinancialContent

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

7.990 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗
ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete. 
Via The Motley Fool
Topics Earnings
News headline image
DiaMedica Therapeutics Q2 Earnings Call Highlights ↗
DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the... 
Via MarketBeat
Topics Earnings
News headline image
DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗
DiaMedica (DMAC) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Exploring DiaMedica Therapeutics's Earnings Expectations ↗
 
Via Benzinga
News headline image
DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗
DiaMedica (DMAC) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Death
News headline image
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress ↗
DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials. 
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Preview: DiaMedica Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Recap: DiaMedica Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
An Overview of DiaMedica Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
DiaMedica Posts Narrower Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Reports Q2 2025 Earnings: Narrower Loss and Promising Clinical Updates Drive Stock Surge ↗
DiaMedica Therapeutics reports Q2 2025 results with a narrower-than-expected loss, positive clinical updates, and strong cash position. Stock surges 19% post-earnings. 
Via Chartmill
News headline image
Earnings Outlook For DiaMedica Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 17, 2025 ↗
 
Via Benzinga
News headline image
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 ↗
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. 
Via InvestorPlace
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 3 Next >